Android app on Google Play

Barclays Keeps 'Overweight' on Alexion Pharmaceuticals (ALXN); Beat & Raise with Three Potential Catalysts Ahead

July 26, 2012 5:35 PM EDT Send to a Friend
Get Alerts ALXN Hot Sheet
Price: $158.67 -0.58%

Rating Summary:
    12 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 21 | New: 42
Trade ALXN Now!
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target of $112.00 (from $104.00).

Analyst, Ying Huang calls Q2 earnings results an impressive beat and raise.

Looking forward Huang said, "Three potential catalysts on the horizon. We look forward to 1) the results of the Phase II investigator trial of Soliris in severe and refractory neuromyelitis optica (NMO), which we expect will be presented at ANA 2012 (Oct 7-9, Boston, MA) or ECTRIMS 2012 (Oct 10-13, Lyon, France); 2) the submission of regulatory filings for Soliris in the STEC-HUS indication (expected by YE'12 or early'13); and 3) Phase I results of ALXN 1102 (formerly TT30), a novel alternative pathway complement inhibitor in PNH."

FY12 EPS estimate raised from $1.79 to $1.87 and FY13 from $2.09 to $2.17.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $105.13 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Barclays, Earnings

Add Your Comment